Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Introduction: Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Karger Publishers 2024-10-01
Serie:	Case Reports in Oncology
Soggetti:	cholangiocarcinoma durvalumab immune thrombocytopenia yttrium-90
Accesso online:	https://beta.karger.com/Article/FullText/541550
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!